Urology Referral

Wembley:
178-190 Cambridge St, Wembley
e: bookings@envisionmi.com.au

Rockingham
2 Civic Boulevard, Rockingham
e: petrockingham@qscan.com.au

Midland
81 Yelverton Drive, Midland
e: midland@qscan.com.au

ENVISION MEDICAL IMAGING | Qscan RADIOLOGY CLINICS

PROUDLY PART OF THE QSCAN GROUP

PATIENT DETAILS

Patient name: DOB: Phone:

Address:

Medicare: Clinical trial / ID no.:

EXAMINATION

- ☐ **PET with Whole Body Diagnostic CT (Head, Chest, Abdo, Pelvis)**
- ☐ **PET with localised diagnostic CT (please tick region/s)**
  - ☐ Head ☐ Neck ☐ Chest ☐ Abdo ☐ Pelvis ☐ Extremity
- ☐ **PET with Non-Diagnostic CT (attenuation correction)**

- ☐ **Contrast Allergy**
- ☐ **Renal Impairment**
- ☐ **Diabetic**

INDICATIONS

MBS ELIGIBLE ITEMS

PSMA

- ☐ Prostate staging (61563)
- ☐ Prostate recurrence (61564)
- ☐ Assessment for suitability of Lu177 PSMA therapy (61528)

Other FDG Avid Cancers

- ☐ Staging (61612)
- ☐ Restaging (61614)

MBS NON ELIGIBLE ITEMS

- ☐ Other FDG PET
- ☐ Other PSMA PET

MBS items must be specialist referred. MBS ineligible items will incur an out of pocket fee.

NUCLEAR MEDICINE

- ☐ Whole body bone scan
- ☐ MAG3 renogram
- ☐ MAG3 renogram with Frusemide
- ☐ DMSA
- ☐ Sestamibi renal scan
- ☐ Other:_____

ULTRASOUND ☐ _____

CT ☐ _____

X-RAY ☐ _____

PROSTATE MRI

For the patient to be eligible for a Medicare rebate one or more of the following criteria must be met.

63541 (1 MRI scan per 12 month period) - Suspected of developing Prostate Cancer based on:

Patient any age:

- ☐ DRE suspicious for prostate cancer

For Patients <70 yrs

- ☐ Minimum of two PSA tests in a 1-3 month period are greater than 3.0 ng/ml, and the free/total PSA ratio is less than 25% or the repeat PSA exceeds 5.5 ng/ml;
- ☐ Family Hx of Ca Prostate, minimum of 2 PSA tests performed within a 1-3 month period are greater than 2.0 ng/ml, and the free/total PSA ratio is less than 25%;

  Note: Relevant family history is a first degree relative with prostate cancer or suspected of carrying a BRCA 1, BRCA 2 mutation.

For Patients 70 yrs or older

- ☐ Minimum of two PSA tests performed within a 1- 3 month period are greater than 5.5ng/ml and the free/total PSA ratio is less than 25%.

63543 Active Surveillance following confirmed diagonsis of prostate cancer by histopathology, and

- ☐ The patient is under active surveillance following a confirmed diagnosis of prostate cancer by biopsy histopathology; and the patient is not planning or undergoing treatment for prostate cancer.

  Note: A period of at least 12 months has elapsed after the use of item 63541, or the initial use of 63543. After the second use of 63543 a patient will only receive a benefit after every 3 year period

CLINICAL NOTES:

REFERRING PRACTITIONER

Name: Provider number:

Follow up appointment: Send copy to:

Signature: Date:

LUNG		
Solitary Pulmonary Nodule	**61523**	Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
NSCLC	**61529**	Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.
BRAIN		
Brain	**61538**	FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.
Epilepsy	**61559**	FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.
Alzheimer's	**61560**	FDG PET brain for diagnosis of Alzheimer's disease if clinical evaluation (by or in consultation with a specialist) is equivocal. Not repeatable within 12 months and not more than 3 per lifetime.
GASTROINTESTINAL		
Colorectal	**61541**	Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
Oesophageal/GOJ	**61577**	Whole body FDG PET study, performed for the staging of proven oesophageal or GOJ carcinoma, in patients considered suitable for active therapy.
GYNAECOLOGY		
Ovarian	**61565**	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
Uterine Cervix	**61571**	Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
Uterine Cervix	**61575**	Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
HEAD & NECK		
Head & Neck	**61598**	Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head & neck cancer.
Head & Neck	**61604**	Whole body FDG PET study performed for the evaluation of patients with suspected residual head & neck cancer after definitive treatment, and who are suitable for active therapy.
MELANOMA		
Melanoma	**61553**	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
SCC		
Metastatic SCC unknown primary	**61610**	Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
LYMPHOMA		
Lymphoma	**61620**	Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma.
Lymphoma	**61622**	Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma.
Lymphoma	**61628**	Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma.
Lymphoma	**61632**	Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma.
SARCOMA		
Bone or Soft Tissue Sarcoma	**61640**	Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
Sarcoma	**61646**	Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.
BREAST		
PET Breast	**61524**	Whole body FDG PET study, performed for the staging of locally advanced (stage III) breast cancer, for a patient who is considered suitable for active therapy (R) (Anaes).
PET Breast	**61525**	Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R) (Anaes).
PSMA		
Prostate Staging	**61563**	Whole Body PSMA PET for initial staging of intermediate to high risk prostate adenocarcinoma for previously untreated patient, considered for locoregional therapy with curative intent. Once per lifetime.
Prostate Recurrence	**61564**	Whole body PSMA PET for restaging of recurrent prostate adenocarcinoma of patient who has undergone prior locoregional therapy and considered suitable for further locoregional therapy to determine appropriate further therapy. Twice per lifetime.
Lutetium 177	**61528**	Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.
OTHER FDG AVID CANCERS		
Staging	**61612**	Whole body FDG PET study for the initial staging of cancer, for a patient who is considered suitable for active therapy, if: (a) the cancer is a typically FDG-avid cancer; and (b) there is at least 10% likelihood that a PET study result will inform a significant change in management for the patient. Applicable once per cancer diagnosis.
Restaging	**61614**	61614: Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy, if the cancer is a typically FDG-avid cancer (R)
OCTREOTATE		
Gastro entero pancreatic NET	**61647**	Whole body 68Ga DOTA peptide PET study.

All images are digitally archived for ten years and can be accessed by your doctor online anytime. Your doctor has recommended you attend Envision Medical Imaging or Qscan Radiology Clinics. You may choose another provider but please discuss this with your doctor first.

13105-02-0825